TBC1 domain family member 32Genealiases: ALHSA · BROMI · C6orf170 · C6orf171 · OFD9 · RP100
Q-omics provides the consensus-scored TBC1D32 profile across patient tissues and cancer cell-line models. TBC1D32 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBC1D32 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TBC1D32 RNA expression shows 21,160 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where TBC1D32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D32 survival associations across molecular data types. TBC1D32 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D32 RNA expression–survival associations across cancer types. High TBC1D32 expression shows unfavorable associations in HNSC and OV, but favorable associations in UCS, READ, SKCM and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBC1D32 RNA expression.
This table summarizes TBC1D32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D32 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, BLCA and STAD. The HNSC box plot shows higher TBC1D32 RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with TBC1D32 in patient tissues and cancer cell lines. In patient samples, TBC1D32 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
